ZP
DYN icon

Zimmer Partners’s Dyne Therapeutics DYN Stock Holding History

Zimmer Partners’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,000
Closed -$202K – 136
2020
Q3 		$202K Buy
+10,000
New +$219K ﹤0.01% 119

Other funds holding DYN

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Zimmer Partners's DYN Position: Q4 2020 in Review

Zimmer Partners sold out of Dyne Therapeutics (DYN) in Q4 2020, closing a stake of 10,000 shares — an estimated $202K sold.

Zimmer Partners first reported a position in DYN in Q3 2020 and held it in 1 quarter. The position peaked at $202K in Q3 2020. 69 funds tracked by Wall St. Rank hold DYN as of Q4 2020.

  • Zimmer Partners reported no remaining Dyne Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Zimmer Partners sold 10,000 Dyne Therapeutics shares in Q4 2020, an estimated $202K.
  • Zimmer Partners first reported a position in Dyne Therapeutics in Q3 2020 and held it in 1 quarter.
  • Zimmer Partners's Dyne Therapeutics position peaked at $202K in Q3 2020.
  • 69 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2020.

Based on Zimmer Partners's 13F filing for Q4 2020, filed 16 Feb 2021.